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27 Context Randomised controlled trials in non-alcoholic fatty liver disease (NAFLD) have shown that 
28 regular exercise, even without calorie restriction, reduces liver steatosis. A previous study has shown 
29 that 16 weeks supervised exercise training in NAFLD did not affect total VLDL kinetics.
30 Objective To determine the effect of exercise training on intrahepatocellular fat (IHCL) and the 
31 kinetics of large triglyceride-(TG)-rich VLDL1 and smaller denser VLDL2 which has a lower TG 
32 content.
33 Design A 16 week randomised controlled trial.
34 Patients 27 sedentary patients with NAFLD.
35 Intervention Supervised exercise with moderate-intensity aerobic exercise or conventional lifestyle 
36 advice (control).
37 Main outcome Very low density lipoprotein1 (VLDL1) and VLDL2-TG and apolipoproteinB (apoB) 
38 kinetics investigated using stable isotopes before and after the intervention. 
39 Results In the exercise group VO2max increased by 31±6% (mean±SEM) and IHCL decreased from 
40 19.6% (14.8, 30.0) to 8.9% (5.4, 17.3) (median (IQR)) with no significant change in VO2max or IHCL 
41 in the control group (change between groups p<0.001 and p=0.02, respectively). Exercise training 
42 increased VLDL1-TG and apoB fractional catabolic rates, a measure of clearance, (change between 
43 groups p=0.02 and p=0.01, respectively), and VLDL1-apoB production rate (change between groups 
44 p=0.006), with no change in VLDL1 -TG production rate. Plasma TG did not change in either group.  
45 Conclusion An increased clearance of VLDL1 may contribute to the significant decrease in liver fat 
46 following 16 weeks of exercise in NAFLD. A longer duration or higher intensity exercise 
47 interventions may be needed to lower plasma TG and VLDL production rate.
48
349 Introduction
50 NAFLD, the most prevalent liver disease in the developed world (1), increases the risk of chronic 
51 liver disease, hepatocellular carcinoma and cardiovascular disease, and is associated with increased 
52 visceral fat, hypertriglyceridaemia and insulin resistance (2). 
53 Hepatic steatosis is the result of an imbalance between triglyceride (TG) synthesis and TG export. 
54 TGs stored and secreted by the liver are synthesised from fatty acids generated from three main 
55 sources: hepatic de novo lipogenesis; circulating non-esterified fatty acids (NEFA), originating from 
56 adipose tissue; and fatty acids derived from the remnants of the TG rich lipoproteins, VLDL and 
57 chylomicrons (3) which are generated when these lipoproteins are cleared from the circulation by the 
58 lipolytic action of lipoprotein lipase (LPL) and hepatic lipase (4).   
59 VLDL secreted by the liver can be separated into large TG-rich VLDL1 and smaller denser VLDL2 
60 which has a lower TG content. There is evidence that these two VLDL species are independently 
61 regulated (5). VLDL is initially assembled as a primordial particle (pre-VLDL) when apolipoprotein 
62 B100 (apoB) is co-translationally lipidated in the endoplasmic reticulum by microsomal transfer 
63 protein (MTP). Pre-VLDL can either be retained and degraded, or further lipidated to form VLDL2. 
64 This particle
 
can then either be secreted or converted to VLDL1 following the addition of more TG in 
65 the liver. The hydrolysis of VLDL1-TG by lipoprotein lipase (LPL) also generates VLDL2 in the 
66 circulation. Thus VLDL2 has two sources. Insulin regulates VLDL assembly by decreasing apoB 
67 mRNA translation (6), inhibiting the expression of MTP (7) and promoting apoB degradation via 
68 autophagy (8). In NAFLD, with intrahepatic lipids in copious supply, increases in both VLDL-apoB 
69 and VLDL-TG production rate (PR) contribute to the atherogenic lipid profile (9).
70 Lifestyle intervention is the first line of treatment for NAFLD. Weight loss (5-10%) through diet, with 
71 or without exercise, has been shown to reduce hepatic steatosis (10,11).  A number of randomised 
72 controlled trials have also shown that regular exercise, even without calorie restriction, reduces liver 
73 steatosis (12,13). A previous study has shown that 16 weeks supervised exercise training in men and 
74 women with NAFLD did not affect total VLDL kinetics (14). In the current study we examined the 
75 effect of 16 weeks supervised exercise training in men with NAFLD on VLDL1 and VLDL2 kinetics, 
76 using a protocol which we have shown previously to very effective at increasing fitness (15).   
477 Methods
78 Study design The study was approved by the English National Health Service (NHS) Ethics 
79 Committee and the University of Surrey Ethics Committee. The study was performed at one centre, in 
80 Guildford, Surrey. This study is part of a larger collaborative study investigating the metabolic impact 
81 of exercise supervision in patients with NAFLD (16). Informed consent was obtained from the study 
82 participants prior to inclusion into the study.   
83 Study participants Twenty nine sedentary male patients, confirmed to have NAFLD were recruited 
84 through the English NHS primary and secondary care providers in the local area. There were two 
85 dropouts, one in each group. Twenty seven patients completed the study (Table 1) The diagnosis of 
86 NAFLD was made in patients who had been referred for investigation of raised serum transaminases, 
87 indication of hepatic steatosis on ultrasound or by liver biopsy (n=4, two in each group; none of these 
88 patients had non-alcoholic steatohepatitis). It was not possible to exclude NASH from subjects who 
89 were not recruited by biopsy. Patients were excluded if the diagnosis of NAFLD was secondary to 
90 drug treatments, if there was evidence of viral hepatitis, autoimmune hepatitis or primary biliary 
91 cirrhosis, or metabolic disorders, if they had a history of type 2 diabetes mellitus, ischaemic heart 
92 disease or had any contraindications to exercise, clinical hyperlipidaemia (fasting plasma TG >3.0 
93 mmol/l or total cholesterol levels > 7.0 mmol/l), if they were current smokers, had a history of 
94 excessive alcohol intake (weekly consumption of >21 units), had MRI contraindications (cardiac 
95 pacemakers, metal implants), or were taking any fibrates or beta blockers. 
96 Participants were asked to complete a Physical Activity Readiness Questionnaire to identify those not 
97 suitable for physical activity. Motivation was assessed through questions relating to willingness to 
98 increase exercise levels and confidence in complying with exercising four times per week. Suitable 
99 participants were randomised to one of two groups using a list generated by computer randomisation, 
100 (Statistical Analysis System v 9.1, PROC PLAN software). One group received a structured 
101 supervised exercise programme with an exercise physiologist. The other group received standard 
102 lifestyle advice (control group) with no further communication from the exercise physiologist.  Both 
103 groups were asked to continue their usual diet. 
104
5105 Study measurements Prior to and following the 16 week intervention period measurements of 
106 physical fitness (VO2max) were made and a 7 day diet diary was completed.  On a separate visit, 
107 measurements of fasting VLDL1 and VLDL2-apoB and TG kinetics and arterial stiffness (by pulse 
108 wave velocity) were made. Body composition (total, subcutaneous and visceral fat volumes) was 
109 measured by magnetic resonance imaging (MRI) and IHCL, intramyocellular (IMCL) and pancreatic 
110 lipid content was measured by magnetic resonance spectroscopy (1H-MRS). 
111 Physical training protocol Participants allocated to the supervised group exercised at moderate 
112 intensity (40-60% heart rate reserve) for 20 minutes initially (progressing towards 1 hour as the 
113 programme developed) 4-5 times per week for 16 weeks. Types of activities were either gym based 
114 aerobic plus resistance exercise, or outdoor aerobic activities and resistance exercise as discussed with 
115 the exercise physiologist. Participants received weekly exercise supervision by the exercise 
116 physiologist usually in person, otherwise by telephone, to assess their progress.
117 Measurement of VO2max VO2max was performed within four days of the metabolic study using an 
118 electronically braked bicycle ergometer (Lode; Excalibur Sport, Groningen, the Netherlands) 
119 equipped with a computerised breath (oxygen [O2]/carbon dioxide [CO2]) analyser system (Medical 
120 Graphics, St Paul, MN, USA). An electrocardiogram (ECG) was undertaken during the exercise test 
121 to monitor participants’ heart rate and exclude latent ischaemic heart disease. 
122 Measurement of pulse wave velocity is described in the Supplementary Material. 
123 Diet diaries Quantification of dietary intake in all participants was assessed by diet diary, and 
124 analysed by Dietplan 6 (Release 6.60b4 with Windows VistaService Pack 1. Forestfield Software Ltd, 
125 Horsham, West Sussex, UK). 
126 Measurement of body composition and intracellular fat Subjects fasted for 6 hours before the scans. 
127 Whole body MR imaging for body fat content and 1H MRS measurements of pancreatic fat, IHCL and 
128 IMCL (tibialis anterior and soleus muscle) was measured on an Intera 1.5T Achieva multinuclear 
129 system (Philips Medical Systems, Best, Holland) as previously reported (17, 18). NAFLD was defined 
130 as mean IHCL > 5·5%. For more details see the Supplementary Material.
131 Metabolic Study Protocol Participants attended the CEDAR centre, Royal Surrey County Hospital, 
132 Guildford on two occasions before (0 week) and after the intervention (16 weeks). The participants 
6133 were asked to refrain from vigorous exercise for 72h before the study, abstain from drinking alcoholic 
134 beverages for 24h, and attend after an overnight fast.  A primed (1mg/kg) intravenous infusion of 1-
135 13C-leucine (1 mg/kg/h) and a bolus of 2H5 glycerol (75µmol/kg) were administered.  Blood samples 
136 were taken at regular time intervals for 9 hours.
137 Laboratory protocols VLDL1 (Svedberg flotation rate 60–400) and VLDL2 (Svedberg flotation rate 
138 20–60) fractions were isolated from plasma by sequential ultracentrifugation (19). ApoB and TG were 
139 isolated from VLDL1 and VLDL2 hydrolysed, derivatised and isotopic enrichment measured by gas 
140 chromatography mass spectrometry as described in the Supplementary Material. Concentration 
141 measurements are also described in the Supplementary Material.
142 Power calculation The primary endpoint for this study was VLDL-apoB production rate. Based on a 
143 previous study in type 2 diabetes where a 6 month exercise program reduced VLDL-apoB production 
144 rate by 48% (20), the study was powered to detect a 20% within-group reduction in VLDL-apoB 
145 production with 80% power at the 5% level. 
146 Data analysis The measurements of enrichment of free glycerol in plasma and glycerol enrichment of 
147 TG in VLDL1 and VLDL2 particles were used to determine VLDL1 and VLDL2-TG fractional 
148 catabolic rate (FCR) using the modelling software SAAM II (SAAM Institute, Seattle, WA) as 
149 previously described (23).  The model was also used to determine the kinetic parameters of VLDL1 
150 and VLDL2 apoB using plasma αKIC enrichment and 1-13C leucine enrichment of VLDL1 and 
151 VLDL2-apoB. VLDL1-TG and apoB FCR had two components, VLDL1 FCR transfer (to VLDL2) and 
152 VLDL1 FCR catabolism (direct removal from circulation). Production rate (PR) was calculated as the 
153 product of VLDL1 and VLDL2-FCR and their respective pool sizes. VLDL1 and VLDL2-TG and apoB 
154 pool sizes were calculated from VLDL1 and VLDL2-TG and apoB concentrations in 
155 ultracentrifugation fractions and plasma volume as previously described (21). (For more details of the 
156 models see the Supplementary Material). Total VLDL-TG and VLDL-apoB pool sizes were 
157 calculated by the addition of VLDL1 and VLDL2-TG and apoB pool sizes respectively. Particle sizes 
158 of VLDL1 and VLDL2 were calculated by dividing TG pool size by apoB pool size. Total VLDL-TG 
159 PR was calculated by summation of VLDL1-TG PR and VLDL2-TG hepatic PR. 
160
7161 Ten-year cardiovascular risk was calculated using the 10 year Framingham Risk Score (FRS) (22). 
162 Homeostatic Model Assessment (HOMA2) was used to assess whole body insulin sensitivity 
163 (HOMA2-%S) (23).  Adipose tissue insulin resistance (Adipo-IR) was calculated by multiplying 
164 fasting plasma NEFA concentration with fasting serum insulin concentration. 
165 Percent Change in IHCL was calculated as Pre-Post intervention/Pre x100. Changes in other 
166 measurements were calculated as Pre-Post intervention.
167
168 Statistical analysis Statistical analysis of the data was performed using SPSS version 21.0 for 
169 Window (Chicago: SPSS Inc.). IHCL is shown as median (interquartile range). All other results are 
170 means ± SEM. Non parametric data was log-transformed. Basal comparisons were performed using 
171 Student’s t test. Within-group changes between baseline and 16 weeks were compared using paired t 
172 tests. The change between baseline and 16 weeks was compared between groups using student’s t test 
173 for parametric data and Mann-Whitney U test for nonparametric data. Correlations were assessed by 
174 Pearson’s correlation coefficient and Spearman’s rho correlation coefficient when the data were not 




179 Body weight, BMI and baseline biochemical characteristics (plasma lipid profile and liver enzyme 
180 concentrations) were not significantly different at 0 weeks between groups (Table 1). Similarly, there 
181 were no significant baseline differences in cardiorespiratory fitness (VO2max), IHCL, pancreatic fat or 
182 fat distribution (Table 2). IHCL in all participants (n=27) at 0 week correlated positively with fasting 
183 plasma TG concentration (r=0.439, p=0.02) and abdominal visceral fat (r=0.411, p=0.03). 
184
185 Effects of intervention (exercise training vs. control)
186 Body weight, BMI and fitness  
187 Body weight and BMI decreased by 3.6±0.8% and 3.8±0.9% respectively after 16 weeks exercise 
188 training with no change in controls (change exercise vs. change control p<0.001 and, p=0.02) (Table 
189 1). In both groups, total energy intake and macronutrient composition remained unchanged after 16 
190 weeks compared with baseline (Supplementary Table 1). 
191 In the exercise group VO2max increased significantly by 31±6% after 16 weeks with no change in 
192 controls (change in exercise group vs. control, p<0.001) (Figure 1, Table 1). 
193 Liver enzymes (Table 1) 
194 After 16 weeks intervention there were within group decreases in the exercise group in ALT, AST and 
195 GGT concentrations (p<0.01, p<0.02 and p<0.03, respectively). ALT also decreased in controls 
196 (p<0.04) with no change in either AST or GGT.
197 Body composition and ectopic fat (Table 2)
198  After 16 weeks, there was a significant decrease in IHCL content (% decrease 52.2% (29.0, 61.8); 
199 median (IQR)) in the exercise group, with no change in controls (change exercise vs. change control 
200 p=0.02). There was no significant change in pancreatic fat. All measured adipose tissue depots also 
201 significantly decreased with no change in controls (Table 2). The percentage change in IHCL between 
202 0 and 16 weeks in all patients (exercise and control group) correlated negatively with the change in 
9203 VO2max (r=-0.45, p<0.02) and correlated positively with the change in total body fat and visceral fat (; 
204 r=0.54, p=0.004; r=0.41, p=0.03).
205 Insulin sensitivity, fasting plasma insulin and glucose concentration (Table 1)
206 After 16 weeks exercise there was a within-group decrease in fasting plasma glucose and serum 
207 insulin concentrations in the exercise group (both p<0.01) (between groups for insulin, p=0.02). 
208 HOMA2-%S (a measure of insulin sensitivity) increased by 42.5±11.6% in the exercise group 
209 (p=0.002) with no change in controls (between group, p=0.003).  
210 Blood pressure, pulse wave velocity and Framingham risk factor scores (Table 2) 
211 Both systolic and diastolic blood pressure measurements decreased by 5.4±1.8% and 6.2±2.7% in the 
212 exercise group after 16 weeks exercise (p=0.01, p=0.04) (between groups p=0.04, p=0.02 
213 respectively). After 16 weeks, pulse wave velocity, a measure of atrial elasticity, improved in the 
214 exercise group (p=0.05) although between groups this was not significant. The Framingham risk score 
215 decreased 14±4% (p=0.001) after exercise with no change in controls (between groups, p<0.05). The 
216 percentage change in IHCL between 0 and 16 weeks in all patients correlated positively with the 
217 change in the FRS (r=0.62, p=0.001).
218 Plasma and fraction lipids (Tables 1, 3 and 4)
219 At baseline, there were no differences in plasma or lipoprotein fraction lipids between groups. Total 
220 cholesterol, TG and HDL cholesterol concentrations did not change from baseline in either group at 
221 16 weeks. After 16 weeks exercise there was a significant within-group decrease (p=0.03) in plasma 
222 LDL cholesterol concentration. NEFA concentration did not change in either group. However adipose 
223 tissue IR decreased by 24±10% in the exercise group (p=0.03) with no change in controls (change 
224 between groups, p=0.02). After 16 weeks there was no significant change in VLDL1-TG or VLDL1 
225 apoB concentration in either group. However VLDL2 TG, cholesterol and apoB concentration were 
226 reduced (p<0.01, p<0.02, p=0.04) in the exercise group with no change in controls. The particle size 
227 of VLDL1 (TG/apoB) was reduced in the exercise group (p=0.03), and was different between groups 
228 (p=0.04). 
10
229 VLDL1- and VLDL2- TG kinetics (Table 3, Figure 2) 
230 At baseline VLDL1 and VLDL2-TG kinetics did not differ between groups. After 16 weeks VLDL1-
231 TG FCR was increased in the exercise group (p<0.05) due to an increase in the VLDL1-TG 
232 catabolism FCR (p=0.05). The percent change in IHCL in all participants was negatively correlated 
233 with the change in VLDL1-TG catabolism FCR (r=-0.74, p<0.001) (Fig 2) and positively correlated 
234 with the change in VLDL1-TG transfer FCR (r=0.63, p=0.001). There was no change in VLDL2-TG 
235 FCR, VLDL1-TG PR, VLDL2-TG PR and total VLDL-TG PR within or between groups. 
236 VLDL1- and VLDL2 ApoB kinetics (Table 4, Figure 2) 
237 VLDL1- and VLDL2-apoB kinetics were not different at baseline between groups. VLDL1-apoB FCR 
238 was increased at 16 weeks in the exercise group (p=0.02) with no change in controls (between groups, 
239 p=0.01).  This was due to a increase in the catabolism FCR (p<0.01) while the transfer FCR (to 
240 VLDL2) was decreased (p=0.005). There was no change in VLDL2-apoB FCR. VLDL1-apoB PR and 
241 total VLDL-apoB PR increased in the exercise group (p= 0.003, p=0.004) (between groups p=0.006, 
242 p=0.02).   The percent change in IHCL between 0 and 16 weeks in all participants correlated 
243 negatively with the change in VLDL1-apoB PR (r=-0.48, p=0.01) (Fig 2).
11
245 Discussion
246 We have demonstrated for the first time that a 16 week supervised exercise intervention which 
247 significantly improved cardiorespiratory fitness and reduced liver fat by over 50% in men with 
248 NAFLD increased the FCR (a measure of clearance) of both VLDL1-TG and apoB.  
249 It is well documented that VLDL1-TG and apoB FCR increases with acute exercise (24) but this effect 
250 is not sustained 48h after exercise (25). In the current study subjects abstained from exercise for 72h 
251 prior to the measurement of VLDL kinetics in order to measure the chronic, rather than the acute, 
252 effects of exercise. NAFLD is highly associated with peripheral and hepatic insulin resistance (26,27), 
253 as observed in our participants who had a fasting insulin concentration double that reported in healthy 
254 subjects.  There was an improvement in insulin sensitivity, as measured by HOMA %S, with exercise 
255 training, as has also been demonstrated previously in type 2 diabetes mellitus and overweight subjects 
256 (20,15). We have also shown in a different subset of patients with NAFLD that 4 months of exercise 
257 training (with a similar-sized effect on fitness and IHCL to the current study) improved peripheral but 
258 not hepatic insulin sensitivity (16). In the current study an improvement in peripheral insulin 
259 sensitivity was also demonstrated with the decrease in adipose-IR. LPL activity is regulated by insulin 
260 (28) and 20-weeks endurance exercise training in healthy men, which increased VO2max by 13%, has 
261 previously been shown to significantly increase post-heparin plasma lipoprotein lipase (29). Increased 
262 LPL activity would provide a mechanism for the increase in VLDL1-TG and apoB FCR observed in 
263 the current study. Notably for VLDL1-TG and apoB FCR it was the catabolic pathway that was 
264 increased rather than the transfer of TG to VLDL2. The increased clearance of TG from the systemic 
265 circulation, while the production rate of TG was simultaneously maintained, would enable the liver to 
266 export some of the stored TG for hydrolysis in skeletal muscle to sustain increased demand for fatty 
267 acids during exercise. 
268 The reduction in body weight in the exercise group is unlikely to have mediated the increase in 
269 VLDL1-TG and apoB clearance since previous studies have shown weight loss in obese men, 
270 following a low calorie diet, reduces VLDL-apoB production rate with no effect on VLDL-apoB FCR 
12
271 (30). Similarly in obese women, a hypocaloric diet has been shown to have no effect on either VLDL-
272 TG or VLDL-apoB FCR (31).
273 The failure of exercise training to lower VLDL1-apoB and TG production rate and to increase 
274 VLDL1-apoB production rate was unexpected. This differs from a study in patients with type 2 
275 diabetes where exercise training for 6 months, resulting in a 16% increase in VO2max, reduced VLDL-
276 apoB production rate (20). Liver fat was not measured in the latter study, patients were on oral 
277 hypoglycemic treatment (metformin and sulphonylureas) and some of the participants were African-
278 Caribbean, a group known to have a lower propensity for NAFLD (32). The increase in VLDL1-apoB 
279 production rate following exercise training in the current study may be explained by the marked 
280 decrease in fasting insulin concentration in response to the improved peripheral insulin sensitivity, 
281 while at the same time hepatic insulin resistance was maintained. Insulin regulates VLDL assembly 
282 (6,7,8), thus a lowering of insulin will increase apoB secretion. It has also been shown in mice that 
283 triglycerides can rescue apoB from posttranslational degradation (33).  The up-regulation of VLDL1-
284 apoB production rate in response to exercise training could increase TG export and therefore assist in 
285 the reduction of liver fat. This could also explain the maintenance of plasma TG levels despite a 
286 decrease in liver fat.
287 The findings of this study differ from a previous study of patients with NAFLD where 16 weeks 
288 exercise training at an exercise intensity comparable to the current study had no effect on VLDL-TG 
289 and apoB kinetics (14). The discordant findings most likely reflect a greater improvement in both 
290 cardiorespiratory fitness and thus a greater reduction in IHCL in our study participants. VO2max 
291 increased by 31% in the current study compared to only a 9% increase in the previous study (14). An 
292 alternative or additional explanation is that total VLDL-TG and apoB (sf 20-400) were measured in 
293 the previous study, rather than VLDL1 and VLDL2 as in the current study.  There is evidence that 
294 VLDL1 and VLDL2 are independently regulated (5) and that exercise primarily affects VLDL1 
295 kinetics (34), and so the effect of exercise on VLDL1 may not be revealed by measurements on total 
296 VLDL. VLDL1 carries more TG compared to VLDL2 per particle and LPL has been shown to have a 
297 preference for TG-rich particles (35). 
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298 In NAFLD, CV events are the most common cause of mortality (36).  Both the FRS, which has been 
299 shown to accurately predict the actual 10-year CV disease risk in patients with NAFLD (37), and 
300 arterial stiffness, an indicator of CVD and independent predictor of the corresponding risk and LDL 
301 cholesterol were decreased following exercise training. The reduced LDL cholesterol may be related 
302 to the small weight loss (38). These measures demonstrate that 16 weeks exercise training can reduce 
303 CVD risk in NAFLD. 
304 The correlation between liver fat and cardiorespiratory fitness suggests the latter is the main driver for 
305 reduced IHCL in the exercise group. However the small weight loss in the exercise group will have 
306 contributed to the reduction in IHCL (11). Both endurance and resistance exercise with and without 
307 weight loss have been shown to reduce liver fat (39). The decrease in IHCL following exercise was 
308 not accompanied by any change in IMCL. This has also been reported in a previous exercise study in 
309 obese subjects (13). A recent meta-analysis of 33 studies examining the effect of lifestyle 
310 interventions on ectopic fat deposition in overweight and obese adults showed only a non-significant 
311 trend toward reductions in IMCL (40). Although the meta-analysis suggested pancreatic fat reduced 
312 with exercise, this was not found in the current study. There have been few studies specifically 
313 addressing effects of exercise intervention on pancreatic fat.
314 In conclusion, with an exercise intervention in non-diabetic men with NAFLD that significantly 
315 improved fitness and cardio-metabolic health, and produced a significant reduction in IHCL, the liver 
316 continued to export excessive amounts of TG in VLDL. This may reflect the failure to normalise 
317 IHCL and restore hepatic insulin sensitivity. A longer duration or higher intensity exercise 
318 intervention, or a combined approach with calorie restriction, may be required to achieve this and to 
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334 Figure legends
335 Figure 1: VO2max at 0 and 16 weeks in a) Exercise group and b) Control group
336 Figure 2. a) VLDL1 (V1) apoB FCR, b) VLDL1-TG FCR c) VLDL1-apoB production rate and d) 
337 VLDL1-TG production rate, at 0 weeks (solid bar) and 16 weeks (hatched bar) in the exercise and 
338 control groups, e) relationship between percent change in IHCL and the change in VLDL1-apoB 
339 production rate and f) relationship between percent change in IHCL and the change in VLDL1-TG 
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Age yr 52.4 ±.2.2 52.8±3.0 NS
Body weight kg 101.3±2.64 97.3±12.2 <0.001 102.3±6.1 102.9±6.4 NS <0.001
BMI kg/m2 31.6±0.8 30.5±1.0 <0.001 31.7±1.0 31.6±1.2 NS 0.02
Waist circumference
cm
109.3±1.9 105.0±2.5 0.005 110.0±3.9 109.6±4.3 NS 0.03
VO2max
ml kg-1 min-1
25.5±1.1 33.0±1.5 <0.001 23.3±1.0 23.8±1.3 NS <0.001
Fasting glucose 
mmol/l
6.0±0.2 5.8±0.2 0.005 5.9±0.2 5.6±0.1 0.02 NS
Fasting insulin 
pmol/l
183±17 138±16 0.007 164±17 170±17 NS 0.02
HOMA2 %S 32.5±2.9 45.6±4.9 0.002 36.1±3.7 34.5±3.2 NS 0.003
Adipose tissue-IR 79.8±8.0 58.2±8.8 0.03 75.9±9.4 86.6±15.7 NS 0.02
NEFA mmol/l 0.45±0.03 0.41±0.04 NS 0.48±0.05 0.50±0.05 NS NS
Total Cholesterol 
mmol/l
5.0±0.2 4.7±0.2 NS 5.1±0.2 5.1±0.2 NS NS
TG mmol/l 2.0±0.2 1.8±0.2 NS 1.6±0.2 1.9±0.2 NS NS
LDL-Cholesterol 
mmol/l
3.8±0.1 3.3±0.2 0.03 3.6±0.2 3.2±0.2 0.07 NS
HDL-Cholesterol 
(mmol/l
1.01±0.06 1.03±0.06 NS 1.09±0.09 1.09±0.08 NS NS
Alanine transaminase 
U/l
51.1±5.3 36.8±5.2 0.01 40.9±6.2 31.1±4.7 0.04 NS
Aspartate 
transaminase U/l
36.9±3.2 29.4±3.5 0.02 29.0±2.5 26.3±1.84 NS NS
Gamma glutamyl 
transaminase U/l
53.5±10.2 36.3±7.5 0.03 37.0±4.5 33.8±4.9 NS NS
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IHCL % 19.6(14.8,30.0) 8.9(5.4,17.3) <0.001 12.5(6.9,32.9) 12.6(9.2,26.1) NS 0.02
IMCL (Sol) 21.7 ± 3.8 19.0 ± 3.5 0.09 19.2±1.8 20.5 ± 2.6 NS 0.07
IMCL (Tib) 8.8 ± 1.0 8.8 ± 1.4 NS 13.2±5.4 8.2 ± 1.2 NS NS
Pancreatic 
fat




9.5 ± 0.6 7.9 ± 0.6 <0.001 9.9 ± 0.9 9.6 ± 0.9 NS 0.03
Visceral Fat
kg




7.0 ± 7.2 6.3 ± 0.7 <0.001 7.8 ± 1.0 7.91 ± 1.1 NS 0.003
Total body 
fat kg
31.6±2.0 27.3±1.9 <0.001 34.8 ± 3.2 34.5 ± 3.5 NS 0.004
Total subcut 
fat kg
22.1 ± 1.7 19.5 ± 1.6 <0.001 24.9 ± 2.4 24.9 ± 2.6 NS 0.001
Systolic BP 
mm Hg 133.4 ± 4.2 128.8 ± 4.2 0.01 131.3 ± 4.5 134.4 ± 3.8 NS 0.04
Diastolic BP
mm Hg 83.4 ± 2.3 78.2 ± 2.6 0.04 83.8 ± 3.0 86.3 ± 3.0 NS 0.02
PWV (m/s) 7.94 ± 0.26 7.67 ± 0.25 0.05 7.58 ± 0.27 7.77 ± 0.28 NS NS
Framingham 
Risk scores
14.4 ± 1.4 12.4 ± 1.4 0.001 14.2 ±2 .5 13.6 ± 1.9 NS <0.05
Intrahepatocellular fat (IHCL) presented as median (interquartile range)
Sol, soleus; Tib, tibialis; visc, visceral; subcut, subcutaneous; PWV, pulse wave velocity
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VLDL1-TG mmol/l 1.24 ±0.15 1.04±0.11 NS 1.00±0.12 1.05±0.15 NS NS
VLDL2-TG
mmol/l
0.17±0.02 0.11±0.01 <0.01 0.13±0.02 0.14±0.02 NS 0.01
VLDL-TG
mmol/l
1.41±0.17 1.15±0.11 <0.01 1.13±0.15 1.19±0.16 NS 0.08
VLDL1 -Chol 
mmol/l
0.31 ±0.04 0.29±0.04 NS 0.29±0.04 0.32±0.05 NS NS
VLDL2-Chol 
mmol/l
0.10 ±0.07 0.07±0.01 <0.02 0.09±0.03 0.09±0.02 NS <0.01
VLDL-Chol 
mmol/l
0.41 ±0.04 0.36±0.04 0.02 0.38±0.06 0.40±0.06 NS 0.01
VLDL1-TG FCR 
pools/d*








1.22±0.16 1.44±0.38 NS 1.63±0.48 2.71±1.35 NS NS
VLDL1-TG PR 
mg/kg/d*
230.9 ±20.3 232.5±12.9 NS 218.4±30.6 213.9±24.1 NS NS
VLDL2-TG FCR 
pools/d**
10.44 ±0.70 11.62±1.48 NS 12.05±1.52 13.16±3.18 NS NS
VLDL2-TG PR 
mg/kg/d**




5.03±0.83 4.23±0.93 NS 6.7±1.3 8.3±3.1 NS NS 
VLDL-TG PR
mg/kg/d**




35.7 ± 4.7 29.7±4.6 NS 30.9±4.8 41.3±8.5 NS NS
*n=13 and **n=12 in exercise group due to problems with sample analysis
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18.4±2.2 20.2±2.8 NS 16.7±1.5 17.3±2.3 NS NS
VLDL2 -apoB 
concentration mg/l
12.9±1.4 9.7±1.0 0.04 11.2±1.8 11.1±1.1 NS NS
VLDL1–
TG/V1apoB 
66.2±7.0 49.8±4.0 0.03 56.5±7.2 60.12±8.7 NS 0.04
VLDL2–
TG/V2apoB 
12.9±1.5 11.6±1.1 NS 12.1±1.4 14.8±3.5 NS NS
VLDL1-apoB FCR 
pools/day








1.19±0.16 0.54±0.1 0.005 1.04±0.25 0.99±0.3 NS 0.06
VLDL2 –apoB 
FCR pools/day
12.3±1.3 11.8±1.3 NS 16.9±3.0 12.9±1.8 NS NS
VLDL1-apoB PR 
mg/kg/d
3.67±0.65 5.54±0.49 0.003 4.92±0.80 3.96±0.60 NS 0.006
VLDL2-apoB PR 
mg/kg/d




0.52±0.09 0.50±0.10 NS 0.74±0.23 0.89±0.24 NS NS
VLDL1- to VLDL2
transfer mg/kg/d
3.52±0.04 2.72±0.01 NS 4.19±1.09 3.09±0.69 NS 0.013
VLDL apoB PR 
mg/kg/d






















































































































































Delta VLDL1-TG Catabolism 
(pools/ day)
r=-0.737
p<0.001
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